Anti‐mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin‐10 knockout mice with spontaneous chronic colitis

Intestinal inflammation causes tight junction changes and death of epithelial cells, and plays an important role in the development of Crohn's disease (CD). CD52 monoclonal antibody (CD52 mAb) directly targets the cell surface CD52 and is effective in depleting mature lymphocytes by cytolytic effects in vivo, leading to long‐lasting changes in adaptive immunity. The aim of this study was to investigate the therapeutic effect of CD52 mAb on epithelial barrier function in animal models of IBD. Interleukin‐10 knockout mice (IL‐10−/−) of 16 weeks with established colitis were treated with CD52 mAb once a week for 2 weeks. Severity of colitis, CD4+ lymphocytes and cytokines in the lamina propria, epithelial expression of tight junction proteins, morphology of tight junctions, tumour necrosis factor‐α (TNF‐α)/TNF receptor 2 (TNFR2) mRNA expression, myosin light chain kinase (MLCK) expression and activity, as well as epithelial apoptosis in proximal colon were measured at the end of the experiment. CD52 mAb treatment effectively attenuated colitis associated with decreased lamina propria CD4+ lymphocytes and interferon‐γ/IL‐17 responses in colonic mucosa in IL‐10−/− mice. After CD52 mAb treatment, attenuation of colonic permeability, increased epithelial expression and correct localization of tight junction proteins (occludin and zona occludens protein‐1), as well as ameliorated tight junction morphology were observed in IL‐10−/− mice. CD52 mAb treatment also effectively suppressed the epithelial apoptosis, mucosa TNF‐α mRNA expression, epithelial expression of long MLCK, TNFR2 and phosphorylation of MLC. Our results indicated that anti‐CD52 therapy may inhibit TNF‐α/TNFR2‐mediated epithelial apoptosis and MLCK‐dependent tight junction permeability by depleting activated T cells in the gut mucosa.

[1]  G. Wu,et al.  Oral treatment with SEW2871, a sphingosine‐1‐phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin‐10 gene deficient mice , 2014, Clinical and experimental immunology.

[2]  L. Gu,et al.  Intestinal dysbacteriosis contributes to decreased intestinal mucosal barrier function and increased bacterial translocation , 2014, Letters in applied microbiology.

[3]  Juan Shi,et al.  TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate‐induced colitis and colitis‐associated carcinogenesis , 2014, Immunology.

[4]  Jie-shou Li,et al.  Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice , 2013, British Journal of Nutrition.

[5]  G. Rogler,et al.  Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice , 2013, Mucosal Immunology.

[6]  C. Abraham,et al.  TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. , 2013, Gastroenterology.

[7]  H. Yin,et al.  Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis , 2013, Immunology.

[8]  V. Verhasselt,et al.  Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation , 2013, Gut.

[9]  B. Wiedenmann,et al.  Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[10]  Takuya Suzuki,et al.  Supplemental naringenin prevents intestinal barrier defects and inflammation in colitic mice. , 2013, The Journal of nutrition.

[11]  C. López-Otín,et al.  Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF , 2013, EMBO molecular medicine.

[12]  M. Grisham,et al.  Iron Status, Anemia, and Plasma Erythropoietin Levels in Acute and Chronic Mouse Models of Colitis , 2013, Inflammatory bowel diseases.

[13]  M. Manns,et al.  Increased Epithelial Permeability Is the Primary Cause for Bicarbonate Loss in Inflamed Murine Colon , 2013, Inflammatory bowel diseases.

[14]  M. Neurath,et al.  Complex roles of caspases in the pathogenesis of inflammatory bowel disease. , 2013, Gastroenterology.

[15]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[16]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[17]  Bin Wang,et al.  Bifidobacteria may be beneficial to intestinal microbiota and reduction of bacterial translocation in mice following ischaemia and reperfusion injury , 2012, British Journal of Nutrition.

[18]  T. Macdonald,et al.  What's the next best cytokine target in IBD? , 2012, Inflammatory bowel diseases.

[19]  Sambasiva P Rao,et al.  Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis , 2012, PloS one.

[20]  J. Schulzke,et al.  Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics , 2012, The Journal of physiology.

[21]  G. Corazza,et al.  New Pathogenic Paradigms in Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[22]  N. Young,et al.  Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. , 2012, Blood.

[23]  C. Hong,et al.  The bone morphogenetic protein–hepcidin axis as a therapeutic target in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[24]  Li-Ling Wu,et al.  Epithelial inducible nitric oxide synthase causes bacterial translocation by impairment of enterocytic tight junctions via intracellular signals of Rho-associated kinase and protein kinase C zeta* , 2011, Critical care medicine.

[25]  M. Zeitz,et al.  Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease , 2011, Gut.

[26]  J. Bluestone,et al.  Control of TH17 cells occurs in the Small Intestine , 2011, Nature.

[27]  W. Koltun,et al.  Increase in the Tight Junction Protein Claudin-1 in Intestinal Inflammation , 2011, Digestive Diseases and Sciences.

[28]  N. Li,et al.  Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice. , 2011, Inflammatory bowel diseases.

[29]  Fiona Powrie,et al.  Intestinal homeostasis and its breakdown in inflammatory bowel disease , 2011, Nature.

[30]  S. Travis,et al.  IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.

[31]  C. Mulder,et al.  Estrogen receptor-β signaling modulates epithelial barrier function. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[32]  P. Rutgeerts,et al.  Effects of T cell‐induced colonic inflammation on epithelial barrier function† , 2010, Inflammatory bowel diseases.

[33]  C. Weber,et al.  Epithelial Myosin Light Chain Kinase Activation Induces Mucosal Interleukin-13 Expression to Alter Tight Junction Ion Selectivity* , 2010, The Journal of Biological Chemistry.

[34]  M. Neurath,et al.  Translating inflammatory bowel disease research into clinical medicine. , 2009, Immunity.

[35]  M. Ban,et al.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). , 2009, The Journal of clinical investigation.

[36]  Jie-shou Li,et al.  The suppressive effect of triptolide on chronic colitis and TNF-alpha/TNFR2 signal pathway in interleukin-10 deficient mice. , 2008, Clinical immunology.

[37]  C. Abraham,et al.  IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. , 2006, Gastroenterology.

[38]  U Wahnschaffe,et al.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease , 2006, Gut.

[39]  J. Turner,et al.  Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease , 2006, Laboratory Investigation.

[40]  A. Watson,et al.  Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. , 2005, Gastroenterology.

[41]  A. Cohen,et al.  Tumor Necrosis Factor Receptor Gene Polymorphisms in Crohn's Disease: Association with Clinical Phenotypes , 2005, The American Journal of Gastroenterology.

[42]  D. Elliott,et al.  Heligmosomoides polygyrus inhibits established colitis in IL‐10‐deficient mice , 2004, European journal of immunology.

[43]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[44]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[45]  M. Washington,et al.  KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production. , 2011, Gastroenterology.

[46]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[47]  A. Nusrat,et al.  Epithelial NF-kappaB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation. , 2010, The American journal of pathology.